Multiple Myeloma

[Guest guest]

Hi,

Multiple myeloma is a difficult cancer to treat and is considered

incurable by medical doctors. Sometime vitamin B12 deficiency is associated

with Myeloma.

Previously I posted a journal article showing that Phycocyanin from

Spirulina algae emulates the effect of Erythropoetin, by stimulating bone

marrow cells to make more red and white blood cells.

This article (Reference 1) states that Erythropoetin (EPO) is beneficial in

multiple myeloma and since Phycocyanin from Spirulina mimicks the effect of EPO

one could deduce that Spirulina may also be beneficial in Multiple Myeloma.

Furthermore this article shows that a T-Cell mediation was responsible for

the therapeutic effect. Since we know that both beta glucan and Spirulina

increase production and activity and effectiveness of T-Cells, then we might

conclude that the immune therapy suggested for use on most cancers could also

be useful in Multiple Myeloma.

That would mean taking say 6 to 9 teaspoons of Spirulia daily plus 2 or 3

grams of beta glucan plus 7 to 10 gms of vitamin C daily. Since L-

selenomethionine (1000mcg) plus Vitamin E (1200 I.U.) produces further

increases in levels of antibody cells, then these two products may be useful to

take as well.

The raw vegetable juice diet and fruit (paw paw, pineapple) derived enzyme

therapy may be helpful as well.

moonbeam

Reference 1.

Proc Natl Acad Sci U S A 2001 Apr 24;98(9):5181-6

Related Articles, Books,

LinkOut

Erythropoietin induces tumor regression and antitumor immune

responses in murine myeloma models.

Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N.

Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petach-Tikva

49100, Israel.

Recombinant human erythropoietin (rHuEpo) has been used successfully in the

treatment of cancer-related anemia. Clinical observations with several patients

with multiple-myeloma treated with rHuEpo has shown, in addition to the

improved quality of life, a longer survival than expected, considering the poor

prognostic features of these patients. Based on these observations, we

evaluated the potential biological effects of rHuEpo on the course of tumor

progression by using murine myeloma models (MOPC-315-IgAlambda(2) and 5T33 MM-

IgG(2b)). Here we report that daily treatment of MOPC-315 tumor-bearing mice

with rHuEpo for several weeks induced complete tumor regression in 30-60% of

mice. All regressors that were rechallenged with tumor cells rejected tumor

growth, and this resistance was tumor specific. The Epo-triggered therapeutic

effect was shown to be attributed to a T cell-mediated mechanism. Serum Ig

analysis indicated a reduction in MOPC-315 lambda light chain in regressor

mice. Intradermal inoculation of 5T33 MM tumor cells followed by Epo treatment

induced tumor regression in 60% of mice. The common clinical manifestation of

myeloma bone disease in patients with multiple-myeloma was established in these

myeloma models. Epo administration to these tumor-bearing mice markedly

prolonged their survival and reduced mortality. Therefore, erythropoietin seems

to act as an antitumor therapeutic agent in addition to its red blood cell-

stimulating activity.

PMID: 11309490 [PubMed - in process]